Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2015

View Archived Issues

WOL-074-019 shows efficacy in inflammation models of colitis and psoriasis

Phase I/II and biomarker data of the hypoxia-activated prodrug PR-104 in AML and ALL

Scientists discover divergent urinary metabolic phenotypes between MDD and BD

Galera plans phase II trial of GC-4419 to protect against radiation-induced oral mucositis

VBL Therapeutics plans phase III study of VB-111 plus bevacizumab in recurrent glioblastoma

ImmunoCellular Therapeutics and FDA reach agreement on SPA for ICT-107

KH-176 receives European orphan drug designation for MELAS syndrome

Wilex confirms discontinuation of collaboration between Heidelberg Pharma and Roche

CFDA approves phase I/II/III clinical trials of pirotinib

Dong-A ST to commercialize Acelex in Korea

Merck & Co. and MD Anderson to evaluate pembrolizumab combination therapies for solid tumors

HiFiBiO achieves milestone in Pfizer antibody research collaboration

DIAPH-3 expression predicts tumor response to chemotherapy

Topline results from phase I study of vonapanitase in symptomatic peripheral artery disease

Bioequivalence results announced for an agent for Fabry's disease

Hua Medicine reports phase Ic data on HMS-5552 in type 2 diabetes

LDL-cholesterol reductions observed in phase I study of CAT-2054

Bayer Schering Pharma presents antimitotics

Roche patents new anti-RSV compounds

AbbVie divulges TrKA inhibitors

Confluence Life Sciences introduces TAK1 inhibitors

Boehringer Ingelheim and Circuit Therapeutics collaborate on metabolic disorders

Redx Pharma patents antibacterial agents

HedgePath studies SUBA-Itraconazole in phase IIb study for basal cell carcinoma nevus syndrome

Phase Ib/II trial investigates talimogene laherparepvec with radiotherapy for soft tissue sarcomas

FDA approves Octapharma's WILATE supplement for the management of VWD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...